Clinical and EEG findings in six patients with altered mental status receiving tiagabine therapy.
Tiagabine (TGB), a novel GABA reuptake inhibitor antiepileptic drug, has been reported to induce nonconvulsive status epilepticus (NCSE) in patients with generalized or partial onset seizures. We describe six patients with refractory partial epilepsy treated with add-on TGB. They developed acute intermittent or progressive chronic confusion associated with diffuse slowing of the electroencephalogram (EEG), shortly after an increase in dose of TGB. This remitted in each situation after reduction of the daily dose. The possibility of nonconvulsive status epilepticus or toxic encephalopathy is discussed.
de Borchgrave
V
V
Centre neurologique William Lennox, Université Catholique de Louvain, Allée de Clerlande, 6, B-1340 Ottignies-LLN, Belgium.
Lienard
F
F
Willemart
Th
T
van Rijckevorsel
K
K
D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use*; D002908:Chronic Disease; D003244:Consciousness Disorders / Q000175:diagnosis* / Q000209:etiology*; D004569:Electroencephalography; D004828:Epilepsies, Partial / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D004829:Epilepsy, Generalized / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D009557:Nipecotic Acids / Q000627:therapeutic use*; D012720:Severity of Illness Index; D000078308:Tiagabine
D000927:Anticonvulsants; D009557:Nipecotic Acids; D000078308:Tiagabine